Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pulmonary Embolism III: Nursing Management01:27

Pulmonary Embolism III: Nursing Management

320
A pulmonary embolism occurs when a thrombus, amniotic fluid, tumor tissue, fat, or air embolus blocks one or more pulmonary arteries. Effective nursing management and patient education are crucial for improving outcomes and preventing recurrence.Nursing management starts with obtaining a comprehensive patient history, particularly noting any history of deep vein thrombosis (DVT). Assess for clinical manifestations, including dyspnea, chest pain, crackles, heart murmurs, and signs of right-sided...
320
Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care01:29

Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care

277
Diagnosing Pulmonary EmbolismDiagnosing pulmonary embolism (PE) involves clinical assessment and advanced imaging tests. The preferred diagnostic tool is the spiral (helical) CT scan or CT angiography (CTA), which uses intravenous contrast media to visualize the pulmonary vasculature and identify emboli.A ventilation-perfusion (V/Q) scan is an alternative for patients unable to receive contrast media. This scan includes both perfusion and ventilation scanning. Perfusion scanning involves...
277
Pulmonary Embolism I: Introduction01:29

Pulmonary Embolism I: Introduction

464
Pulmonary embolism (PE) occurs when a thrombus, fat or air embolus, amniotic fluid, or tumor tissue blocks one or more pulmonary arteries. These blockages originate in the venous system or the right side of the heart.EtiologyPE primarily arises from deep vein thrombosis (DVT) and other hypercoagulable states, such as inherited thrombophilias. Additional etiological factors include venous stasis, commonly seen in obesity, and endothelial injury from surgery and trauma. Less common causes include...
464
Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

262
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
262
Pneumothorax-II01:27

Pneumothorax-II

852
Pneumothorax is a medical condition defined by the buildup of air in the pleural space between the lungs and the chest wall. This accumulation of air can lead to partial or complete lung collapse, resulting in a range of clinical manifestations. Understanding the clinical presentation and effective management strategies is crucial for healthcare professionals in providing timely and appropriate care to individuals with pneumothorax.
Clinical Manifestations:
852
Chronic Obstructive Pulmonary Disease-V: Management01:29

Chronic Obstructive Pulmonary Disease-V: Management

3.1K
Managing Chronic Obstructive Pulmonary Disease (COPD) involves a multifaceted approach to reduce symptoms, prevent exacerbations, improve overall health status, and slow disease progression. Key strategies include lifestyle modifications, pharmacotherapy, supportive therapies, and, in some cases, surgery. Here is an overview of the primary COPD management strategies:
Smoking Cessation
3.1K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Another complement inhibitor therapy for myasthenia gravis: Is it NIMBLE enough?

Med (New York, N.Y.)·2026
Same author

Proteomic and machine learning analysis predicts treatment response signatures in Myasthenia Gravis.

Journal of translational medicine·2026
Same author

Limited adoption of thymectomy for nonthymomatous myasthenia gravis.

Journal of thoracic disease·2026
Same author

Construction of patient trajectories to model clinical trial outcomes: application to myasthenia gravis.

Frontiers in digital health·2026
Same author

Thymic health under the microscope.

Nature·2026
Same author

Autologous CD19/BCMA CAR-T cell therapy for myasthenia gravis: Advancing care for those with severe disease.

Med (New York, N.Y.)·2026

Related Experiment Video

Updated: Jan 9, 2026

Pulmonary Embolism III: Nursing Management
01:27

Pulmonary Embolism III: Nursing Management

Published on: June 19, 2025

320

Myasthenia gravis: past, present, and future.

Bianca M Conti-Fine1, Monica Milani, Henry J Kaminski

  • 1Department of Biochemistry, University of Minnesota, Minneapolis, Minnesota 55455, USA. conti001@umn.edu

The Journal of Clinical Investigation
|November 3, 2006
PubMed
Summary

Myasthenia gravis (MG) is an autoimmune disorder where antibodies disrupt neuromuscular junctions, impacting muscle signaling. Understanding these mechanisms improves diagnostics and leads to targeted treatments for MG patients.

More Related Videos

Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care
01:29

Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care

Published on: June 19, 2025

277
Pulmonary Embolism I: Introduction
01:29

Pulmonary Embolism I: Introduction

Published on: June 19, 2025

464

Related Experiment Videos

Last Updated: Jan 9, 2026

Pulmonary Embolism III: Nursing Management
01:27

Pulmonary Embolism III: Nursing Management

Published on: June 19, 2025

320
Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care
01:29

Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care

Published on: June 19, 2025

277
Pulmonary Embolism I: Introduction
01:29

Pulmonary Embolism I: Introduction

Published on: June 19, 2025

464

Area of Science:

  • Neurology
  • Immunology
  • Neuroscience

Background:

  • Myasthenia gravis (MG) is an autoimmune condition affecting neuromuscular transmission.
  • It is characterized by autoantibodies binding to key proteins at the neuromuscular junction (NMJ).

Observation:

  • Antibodies primarily target nicotinic acetylcholine receptors (AChR) or muscle-specific tyrosine kinase (MuSK).
  • This binding impairs signaling, leading to neuromuscular transmission failure.

Findings:

  • Extensive knowledge exists on self-tolerance, anti-AChR antibody synthesis, and AChR function modulation.
  • Mechanisms causing transmission failure upon antibody binding are well-understood.

Implications:

  • Insights have driven advancements in diagnostic methods for MG.
  • This knowledge facilitates the development of targeted immunosuppressive and immunomodulatory therapies.